Trials / Conditions / Primary Myelofibrosis (PMF)

Primary Myelofibrosis (PMF)

17 registered clinical trials studyying Primary Myelofibrosis (PMF) — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis NCT07340138	Novartis Pharmaceuticals	Phase 1
Recruiting	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727	Novartis Pharmaceuticals	Phase 3
Recruiting	A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891	Prelude Therapeutics	Phase 1
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Recruiting	Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis NCT06770842	The University of Hong Kong	Phase 2
Completed	Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis NCT07319026	Fondazione IRCCS Policlinico San Matteo di Pavia	—
Unknown	Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis NCT04878003	Kartos Therapeutics, Inc.	Phase 2
Completed	Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis NCT04217993	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 2
Terminated	Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib NCT03935555	Samus Therapeutics, Inc.	Phase 1
Unknown	KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Ref NCT03662126	Kartos Therapeutics, Inc.	Phase 2 / Phase 3
Active Not Recruiting	Extended Access of Momelotinib in Adults With Myelofibrosis NCT03441113	GlaxoSmithKline	Phase 2
Completed	Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) NCT03136185	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Phase 1 / Phase 2
Completed	Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post NCT02515630	Sierra Oncology LLC - a GSK company	Phase 2
Completed	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myel NCT02101268	Sierra Oncology LLC - a GSK company	Phase 3
Completed	Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibr NCT01558739	Novartis Pharmaceuticals	Phase 4
Completed	Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases NCT00910728	AstraZeneca	Phase 1
Available	Managed Access Programs for INC424, Ruxolitinib NCT04745637	Novartis Pharmaceuticals	—